ClinicalTrials.gg
TerminatedNCT04747431upliFT-DUpdated Oct 29, 2026

A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes

A Phase 1/2 interventional study of PBFT02 in Frontotemporal Dementia, FTD and FTD-GRN, sponsored by Passage Bio, Inc.. Terminated at 10 sites in 5 countries. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Passage Bio, Inc. · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
The PBFT02-001 Study was terminated by the Sponsor, Passage Bio, Inc., due to strategic company resourcing decisions. The early closure is not related to safety, efficacy, or any change in the benefit-risk profile of the investigational product.
Updated Oct 29, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
35 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Frontotemporal Dementia with a site in United States — 31 open to participants now, 45 under way, none of them phase 3. Frontotemporal Dementia · United States.

Enrollment
46th of 66
30 · median 60
Started
2021
with 7 others
Phase 1/2
5 of 103
2 open now
Registered
66th of 103
by date

Among the 103 studies in Frontotemporal Dementia with a site in United States, this one is the 46th largest by enrollment of the 66 interventional ones that give a count, is one of 8 that started in 2021, is one of 5 in phase 1/2, and was the 66th registered.

Frontotemporal Dementia

208 studies on the registry are indexed under Frontotemporal Dementia; 72 are open to participants now.

Browse Frontotemporal Dementia studies →

Open to participants now

31 of the 103 studies in Frontotemporal Dementia with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Frontotemporal Dementia studies recruiting now, 29 (57%) set no upper age limit and 5 (10%) stop at 75 or younger; 6 take children under 18; 30 take healthy volunteers.

This study: 35 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Frontotemporal Dementia with a site in United States, or all of them as a file.
02

Study summary

PBFT02 is a gene therapy for frontotemporal dementia intended to deliver a functional copy of the GRN gene to the brain. This study will assess the safety, tolerability and efficacy of this treatment in patients with frontotemporal dementia and mutations in the granulin precursor (GRN) or chromosome 9 open reading frame 72 (C9ORF72) genes

Read the detailed description

PBFT02 is an adeno-associated viral vector serotype 1 carrying GRN, the gene encoding for human progranulin, formulated as a solution for injection into the cisterna magna. This is a global interventional, multicenter, open-label, single-arm study of PBFT02 delivered as a one-time dose administered into the cisterna magna to participants with FTD-GRN or C9orf72. Participants aged ≥ 35 and ≤ 75 years with early symptomatic FTD-GRN or with symptomatic FTD-C9orf72 may be enrolled into the study.

PBFT02 will be studied in three cohorts of FTD-GRN participants and two cohorts of FTD-C9orf72 participants.

This is a 5-year study, with a 2-year main study, followed by a 3-year safety extension.

03

Conditions studied

  • Frontotemporal Dementia
  • FTD
  • FTD-GRN
  • Dementia Frontotemporal
  • C9orf72

Keywords

  • frontotemporal dementia
  • Progranulin Mutations
  • FTD-GRN
  • Gene Therapy
  • Dementia Gene Therapy
  • AAV1
  • Fronto-temporal Dementia
  • C9orf72
04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Documented to be a pathogenic carrier of GRN or C9orf72 mutation
  2. Clinical diagnosis of frontotemporal dementia
  3. Have a reliable informant / caregiver (and back-up informant / caregiver) who personally speaks with or sees the subject at least weekly
  4. Living in the community (i.e., not in a nursing home); assisted living may be permitted at the discretion of the investigator

Exclusion criteria

Exclusion Criteria:

  1. Classification of the GRN mutation as "not pathogenic," "likely benign variant," "benign variant," or "pathogenic nature unclear" (FTD- GRN Cohorts 1-3) or C9orf72 HRE length ≤ 30 (FTD-C9orf72 Cohorts 4-5).
  2. Previous treatment with any gene therapy. Any other therapies with the potential to alter PGRN levels must be washed out for at least 5 half-lives prior to entry into this study
  3. Homozygous GRN mutation carrier (FTD-GRN Cohorts 1-3) or homozygous C9orf72 mutation carrier (FTD-C9orf72 Cohorts 4-5).
  4. Rosen-modified Hachinski Ischemic Scale score > 7
  5. Known presence of a structural brain lesion (eg, tumor, cortical infarct) that could reasonably explain symptoms in a symptomatic subject
  6. Known presence of an AD-causing mutation in PSEN1, PSEN2 or APP based on genetic testing history (if performed)
  7. Previous history of Korsakoff encephalopathy, severe alcohol or substance dependence (within 5 years of onset of dementia), except where onset of increased alcohol consumption occurs at the time of FTD disease onset
  8. History of untreated vitamin B12 deficiency
  9. Presence of untreated hypothyroidism (thyroid stimulating hormone [TSH] > and free T4 \< LLN)
  10. ≤ 30 ml/min (as calculated using the CKD-EPI equation)
  11. [ALT] or aspartate aminotransferase [AST] > 2 × ULN, or total > ULN)
  12. Respiratory failure that requires supplemental oxygen, tracheostomy, or reliance on non-invasive ventilation for >2 hours during waking hours
  13. Inability to provide full consent or the lack of a legally authorized caregiver with adequate contact who can provide consent
  14. Any to MRI or lumbar puncture (LP) (eg, local infection, history of thrombocytopenia, coagulopathy)
  15. Any contraindication to the ICM administration procedure
  16. Medical conditions or laboratory or vital sign abnormalities that would increase risk of complications from ICM injection, anesthesia, LP, and/or MRI (e.g., fever, hypoxia, tachycardia, or evidence of active infection)
  17. status
  18. Peripheral axonal sensory neuropathy
  19. Receipt of a vaccine within 14 days of dosing
  20. A positive test result for (HIV), human T cell leukemia virus (HTLV) type 1 or type 2, or or C; a Mycobacterium tuberculosis positive test within 1 year of or determined at screening
  21. Malignant neoplasia (except localized skin cancer) or a documented history of hereditary cancer syndrome
  22. Any concurrent disease that, in the opinion of the investigator, may cause cognitive impairment unrelated to GRN or C9orf72 mutations, including other causes of dementia, neurosyphilis, hydrocephalus, stroke, small vessel ischemic disease, uncontrolled hypothyroidism, or vitamin deficiency
  23. Current or recent history of suicidal ideation within the past 6 months
  24. For women of , a positive serum pregnancy test at the screening visit, a positive serum result on Day 1 prior to administration of the product, or unwillingness to have additional pregnancy tests during the study. Women of childbearing potential must use a highly effective method of or engage in abstinence until 90 days postdose
  25. Women who are breastfeeding
  26. For sexually active men, unwillingness to use a medically accepted method of double-barrier contraception (such as a condom/diaphragm used with spermicide) or engage in abstinence from the date of screening until 90 days postdose
  27. Any condition (eg, history of any disease, evidence of any current disease, any finding upon physical examination, or any laboratory abnormality) that, in the opinion of the investigator, would put the subject at undue risk or would interfere with evaluation of the investigational product or interpretation of subject safety or study results
  28. Any acute illness requiring hospitalization within 30 days of enrollment
  29. Failure to meet the protocol-specified coagulation test criteria:

    • count > 100,000 per uL
    • \< 1.5
    • aPTT \< 40 seconds
  30. Use of anticoagulants in the 2 weeks prior to screening
  31. or contraindications to use
  32. Known or suspected intolerance or hypersensitivity to PBFT02 or any of its ingredients or to closely related compounds
  33. Any condition expected to increase risk of thrombosis
  34. Hypersensitivity or contraindications to apixaban

    Additional Criteria for FTD-C9orf72 (Cohorts 4-5) ONLY: Presence of concurrent ALS is permitted provided the following criteria are NOT met:

  35. ALSFRS-R \< 35 at screening.
  36. SVC \< 75% of predicted normal adjusted for sex, age, and height (from the sitting position).
  37. Bulbar-onset ALS.
  38. Current or anticipated need, in the opinion of the Investigator for a diaphragm pacing system (DPS) during the study period.
  39. If taking riluzole or edaravone, participant's dose has not been stable for ≥ 30 days prior to Day 1 and/or dose adjustments are anticipated before the Day 60 study visit.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Drug: PBFT02 Dose 1; Single dose of PBFT02, via intra cisterna magna \*GC/g: gene copy per gram of estimated brain weight

    Drug: PBFT02

  • Experimental
    Cohort 2, 3, 4 and 5

    Drug: PBFT02 Dose 1 or 2; Single dose of PBFT02, via intra cisterna magna \*GC/g: gene copy per gram of estimated brain weight

    Drug: PBFT02

Interventions

  • DrugPBFT02

    PBFT02

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-Related AEs and SAEs

    Assess the number of treatment-related adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Up to 5 years (multiple visits)

  2. Change in Nerve Conduction Velocity and Amplitude from Baseline on Nerve Conduction Studies

    Assess changes in nerve conduction velocity in the distal segments of the sural, radial, and median sensory nerves and peroneal motor nerve as measured on conventional nerve conduction studies.

    Time frame: From baseline to 5 years (multiple visits)

  3. Change in Cellular and Humoral Response Against the Vector and Transgene in Serum

    Assess ELISpot and antibody titers against AAV1 and against human progranulin

    Time frame: From baseline to 5 years (multiple visits)

Secondary outcomes

  1. Change from baseline in CSF and plasma PGRN levels

    Assess effect of treatment with PBFT02 on CSF and plasma PGRN levels following administration of a single ICM dose.

    Time frame: From baseline to 5 years (multiple visits)

  2. Change from baseline in plasma and CSF neurofilament light chain (NfL) levels

    Assess the effect of treatment with PBFT02 on PGRN level in CSF and plasma

    Time frame: From baseline to 5 years (multiple visits)

  3. Change in Brain anatomy as assessed by MRI

    Assess the effect of treatment with PBFT02 on Brain volume, white matter integrity, and cortical thickness as assessed by MRI

    Time frame: From baseline to 5 years (multiple visits)

  4. Change in FTLD disease progression

    Assess changes in the Clinical Dementia Rating Scale for Frontotemporal Lobar Degeneration plus National Alzheimer's Coordinating Center FTLD Behavior \& Language Domains (CDR® plus NACC FTLD SB)

    Time frame: From baseline to 5 years (multiple visits)

  5. Change in ALS disease progression in participants with FTD C9orf72

    Assess changes in ALS disease progression using the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R), percent predicted slow vital capacity (SVC) and in muscle strength as measured by handheld dynamometry (HHD)

    Time frame: From baseline to 5 years (multiple visits)

  6. Change in vital status

    Assess the impact of PBFT02 on survival

    Time frame: From Baseline to 5 years (multiple years)

07

Study locations

10 sites
  • Michigan Alzheimer's Disease Center
    Ann Arbor, Michigan 48105, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • University of Texas at Houston
    Houston, Texas 77030, United States
  • Eastern Health-Box Hill Hospital
    Melbourne, Victoria 3128, Australia
  • Hospital das Clinicas da Universidade Federal de Minas Gerais (UFMG)
    Minas Gerais, Brazil
  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP)
    São Paulo, Brazil
  • University of Toronto, Toronto Western Hospital
    Toronto, Ontario M5T 2S8, Canada
  • Montreal Neurological Institute-Hospital
    Montreal, Quebec H3A 2B4, Canada
  • Centro Hospitalar e Universitário de Coimbra
    Coimbra, Portugal
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2021 to primary completion in Jun 2026, 57 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Aug 2028 → Jun 2026 and completion Aug 2031 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2021
First posted
Feb 10, 2021
StartActual
Sep 14, 2021
Primary completionActual
Jun 19, 2026was Aug 2028
CompletionActual
Jun 19, 2026was Aug 2031
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated The PBFT02-001 Study was terminated by the Sponsor, Passage Bio, Inc., due to strategic company resourcing decisions. The early closure is not related to safety, efficacy, or any change in the benefit-risk profile of the investigational product.
changed Oct 29, 2026
Primary completion
Aug 2028→Jun 19, 2026 (actual)
Oct 29, 2026
Study completion
Aug 2031→Jun 19, 2026 (actual)
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Active, not recruiting→Terminated
    Why stopped The PBFT02-001 Study was terminated by the Sponsor, Passage Bio, Inc., due to strategic company resourcing decisions. The early closure is not related to safety, efficacy, or any change in the benefit-risk profile of the investigational product.
    Primary completion Aug 2028→Jun 19, 2026 (now actual)
    Study completion Aug 2031→Jun 19, 2026 (now actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04747431
Lead sponsor
Passage Bio, Inc.
Responsible party
Sponsor
First posted
Feb 10, 2021
Start date
Sep 14, 2021
Primary completion
Jun 19, 2026
Completion
Jun 19, 2026
Last update
Oct 29, 2026

Study contacts

Chief Medical Officer Chief Medical Officer
study chair · Passage Bio, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion